A systematic review of progress toward unlocking the power of epigenetics in NSCLC

• Verfasst von: Sulewska, Anetta [VerfasserIn]
• Verfasst von: Pilz, Lothar R. [VerfasserIn]
• Verfasst von: Manegold, Christian [VerfasserIn]
• Verfasst von: Ramlau, Rodryg [VerfasserIn]
• Verfasst von: Charkiewicz, Radoslaw [VerfasserIn]
• Verfasst von: Niklinski, Jacek [VerfasserIn]
• Titel: A systematic review of progress toward unlocking the power of epigenetics in NSCLC
• Titelzusatz: latest updates and perspectives
• Verf.angabe: Anetta Sulewska, Lothar Pilz, Christian Manegold, Rodryg Ramlau, Radoslaw Charkiewicz and Jacek Niklinski
• E-Jahr: 2023
• Jahr: 15 March 2023
• Umfang: 33 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 18.07.2024
• Titel Quelle: Enthalten in: Cells
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2023
• Band/Heft Quelle: 12(2023), 6, Artikel-ID 905, Seite 1-33
• ISSN Quelle: 2073-4409
• DOI: doi:10.3390/cells12060905
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: DNA methylation
• Sach-SW: epigenetic therapy
• Sach-SW: lncRNA
• Sach-SW: miRNA
• Sach-SW: NSCLC
• K10plus-PPN: 1895728401

Abstract

Epigenetic research has the potential to improve our understanding of the pathogenesis of cancer, specifically non-small-cell lung cancer, and support our efforts to personalize the management of the disease. Epigenetic alterations are expected to have relevance for early detection, diagnosis, outcome prediction, and tumor response to therapy. Additionally, epi-drugs as therapeutic modalities may lead to the recovery of genes delaying tumor growth, thus increasing survival rates, and may be effective against tumors without druggable mutations. Epigenetic changes involve DNA methylation, histone modifications, and the activity of non-coding RNAs, causing gene expression changes and their mutual interactions. This systematic review, based on 110 studies, gives a comprehensive overview of new perspectives on diagnostic (28 studies) and prognostic (25 studies) epigenetic biomarkers, as well as epigenetic treatment options (57 studies) for non-small-cell lung cancer. This paper outlines the crosstalk between epigenetic and genetic factors as well as elucidates clinical contexts including epigenetic treatments, such as dietary supplements and food additives, which serve as anti-carcinogenic compounds and regulators of cellular epigenetics and which are used to reduce toxicity. Furthermore, a future-oriented exploration of epigenetic studies in NSCLC is presented. The findings suggest that additional studies are necessary to comprehend the mechanisms of epigenetic changes and investigate biomarkers, response rates, and tailored combinations of treatments. In the future, epigenetics could have the potential to become an integral part of diagnostics, prognostics, and personalized treatment in NSCLC.